Agglutinin

Cold Agglutinin Disease 2020 Market Spotlight - Licensing and Asset Acquisition Deals - ResearchAndMarkets.com

Retrieved on: 
Friday, July 3, 2020

This Market Spotlight report covers the Cold Agglutinin Disease market, comprising disease background and treatment information, key pipeline drugs, clinical trials, probability of success, licensing and acquisition deals, and an epidemiology overview.

Key Points: 
  • This Market Spotlight report covers the Cold Agglutinin Disease market, comprising disease background and treatment information, key pipeline drugs, clinical trials, probability of success, licensing and acquisition deals, and an epidemiology overview.
  • There are only two industry-sponsored drugs in active clinical development for cold agglutinin disease, with one drug each in Phase II and Phase III
    Therapies in development for cold agglutinin disease target the complement pathway.
  • There have been only two licensing and asset acquisition deals involving cold agglutinin disease drugs during 2015-20.
  • Sanofi leads industry sponsors with the highest number of clinical trials for cold agglutinin disease.

Cold Agglutinin Disease (CAD) Epidemiology Forecast to 2028: Focus on 10 Emerging Markets - Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China, and Taiwan - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 7, 2019

The "Cold Agglutinin Disease (CAD) - Epidemiology Forecast - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cold Agglutinin Disease (CAD) - Epidemiology Forecast - 2028" report has been added to ResearchAndMarkets.com's offering.
  • Cold Agglutinin Disease (CAD)- Epidemiology Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends of CAD in 10 Emerging Markets (EM) i.e.
  • Turkey, Russia, Saudi Arabia, United Arab Emirates (UAE), Mexico, Colombia, Brazil, Argentina, China, and Taiwan.
  • The total prevalent cases for Cold Agglutinin Disease (CAD) were highest in China, while Russia and U.A.E.

Global Cold Agglutinin Disease Market Spotlight 2019: Key Pipeline Drugs, Clinical Trials, Probability of Success, Licensing, Acquisition Deals, and Epidemiology - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 5, 2019

This Market Spotlight report covers the Cold Agglutinin Disease market, comprising disease background and treatment information, key pipeline drugs, clinical trials, probability of success, licensing and acquisition deals, and an epidemiology overview.

Key Points: 
  • This Market Spotlight report covers the Cold Agglutinin Disease market, comprising disease background and treatment information, key pipeline drugs, clinical trials, probability of success, licensing and acquisition deals, and an epidemiology overview.
  • There are only two industry-sponsored drugs in active clinical development for cold agglutinin disease, with one drug each in Phase II and Phase III.
  • There have been only two licensing and asset acquisition deals involving cold agglutinin disease drugs during 2014-19.
  • Sanofi leads industry sponsors with the highest number of clinical trials for cold agglutinin disease.